# A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

> **NCT00110435** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 1229 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Hypercholesterolemia

## Interventions

- **DRUG:** MK0653A, ezetimibe (+) simvastatin
- **DRUG:** Duration of Treatment: 4 wk placebo run in then 6 wk active
- **DRUG:** Comparator: atorvastatin

## Key facts

- **NCT ID:** NCT00110435
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 1229 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110435, "A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00110435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*